Brief: Recro And Biocorrx Expand Development And Manufacturing Relationship To Support Bicx104, An Implantable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
08/09/2021 12:33
Sept 8 (Reuters) - Recro Pharma Inc REPH.O :
* RECRO AND BIOCORRX EXPAND DEVELOPMENT AND MANUFACTURING
RELATIONSHIP TO SUPPORT BICX104, AN IMPLANTABLE NALTREXONE
PELLET FOR THE TREATMENT OF OPIOID USE DISORDER
* RECRO PHARMA - WILL PROVIDE ANALYTICAL VALIDATION SERVICES
AND
CGMP MANUFACTURING OF REGISTRATIONAL BATCHES OF BICX104
Source text for Eikon: ID:nGNX4kjtB6
Further company coverage: REPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Societal CDMO
See all newsBrief: Corerx Inc Completes Acquisition Of Societal CDMO Inc
Societal CDMO Inc reports results for the quarter ended in December - Earnings Summary
Brief: Societal CDMO Inc Received Notice From Nasdaq Stating Co Regained Compliance With Nasdaq Listing Rule 5550(A)(2) On March 14
Brief: Societal Cdmo Enters Into Definitive Agreement To Be Acquired By Corerx, Inc.
Societal CDMO Inc expected to post a loss of 1 cent a share - Earnings Preview